Scinopharm Taiwan, Ltd.(TW:1789)
NT$20.00-0.25 (-1.23%)
TW:1789
Scinopharm Taiwan, Ltd. financials statements
NT$20.00
At close:-0.25 (-1.23%)
Scinopharm Taiwan, Ltd. (1789) Ratios
Scinopharm Taiwan, Ltd. Ratios
TW:1789's free cash flow for Q2 2026 was NT$219.40M. For the 2026 fiscal year, TW:1789's free cash flow was decreased by NT$-17.62M and operating cash flow was NT$237.02M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.74 | 8.61 | 8.75 | 7.87 | 10.73 |
| Quick Ratio | 5.43 | 6.43 | 6.67 | 6.39 | 8.31 |
| Cash Ratio | 4.38 | 5.43 | 5.40 | 5.35 | 7.34 |
| Solvency Ratio | 0.49 | 0.58 | 0.55 | 0.54 | 0.53 |
| Operating Cash Flow Ratio | 0.84 | 0.98 | 0.32 | 0.96 | 0.92 |
| Short-Term Operating Cash Flow Coverage | 4.58 | 20.42 | 6.94 | 9.82 | 435.00 |
| Net Current Asset Value | NT$ 4.16B | NT$ 5.19B | NT$ 5.02B | NT$ 4.86B | NT$ 4.79B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.06 | 0.05 | 0.06 | 0.05 |
| Debt-to-Equity Ratio | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 |
| Debt-to-Capital Ratio | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.13 | 1.13 | 1.13 | 1.14 | 1.11 |
| Debt Service Coverage Ratio | 4.73 | 18.63 | 17.84 | 9.23 | 81.81 |
| Interest Coverage Ratio | 11.04 | 39.92 | 34.38 | 51.26 | 44.10 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.96 | 0.87 | 0.80 | 0.87 | 0.71 |
| Net Debt to EBITDA | -3.48 | -3.84 | -4.05 | -4.09 | -5.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 34.66% | 38.17% | 38.17% | 38.32% | 46.36% |
| EBIT Margin | 4.97% | 12.36% | 11.24% | 13.66% | 11.18% |
| EBITDA Margin | 21.31% | 26.70% | 25.71% | 27.12% | 24.99% |
| Operating Profit Margin | 3.44% | 9.47% | 9.87% | 12.43% | 10.45% |
| Pretax Profit Margin | 4.66% | 12.13% | 10.95% | 13.42% | 10.94% |
| Net Profit Margin | 4.33% | 9.96% | 9.01% | 10.82% | 8.81% |
| Continuous Operations Profit Margin | 4.33% | 9.96% | 9.01% | 10.82% | 8.81% |
| Net Income Per EBT | 92.93% | 82.16% | 82.29% | 80.65% | 80.54% |
| EBT Per EBIT | 135.32% | 127.98% | 110.92% | 107.97% | 104.69% |
| Return on Assets (ROA) | 1.15% | 2.84% | 2.45% | 2.97% | 2.08% |
| Return on Equity (ROE) | 1.30% | 3.22% | 2.77% | 3.38% | 2.32% |
| Return on Capital Employed (ROCE) | 0.98% | 2.89% | 2.86% | 3.65% | 2.59% |
| Return on Invested Capital (ROIC) | 0.90% | 2.36% | 2.34% | 2.92% | 2.09% |
| Return on Tangible Assets | 1.16% | 2.85% | 2.45% | 2.97% | 2.08% |
| Earnings Yield | 1.01% | 1.95% | 1.37% | 1.76% | 1.25% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.07 | 5.21 | 4.09 | 4.99 | 7.03 |
| Payables Turnover | 33.06 | 26.01 | 19.45 | 16.07 | 21.26 |
| Inventory Turnover | 1.26 | 1.26 | 1.30 | 1.69 | 1.10 |
| Fixed Asset Turnover | 0.75 | 0.74 | 0.70 | 0.68 | 0.57 |
| Asset Turnover | 0.27 | 0.29 | 0.27 | 0.27 | 0.24 |
| Working Capital Turnover Ratio | 0.60 | 0.59 | 0.57 | 0.60 | 0.52 |
| Cash Conversion Cycle | 349.95 | 346.01 | 350.63 | 265.88 | 366.06 |
| Days of Sales Outstanding | 72.00 | 70.10 | 89.35 | 73.08 | 51.93 |
| Days of Inventory Outstanding | 288.99 | 289.95 | 280.04 | 215.51 | 331.29 |
| Days of Payables Outstanding | 11.04 | 14.03 | 18.76 | 22.71 | 17.17 |
| Operating Cycle | 360.99 | 360.05 | 369.39 | 288.59 | 383.23 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.74 | 0.95 | 0.29 | 0.98 | 0.64 |
| Free Cash Flow Per Share | 0.38 | 0.58 | -0.07 | 0.66 | 0.24 |
| Dividend Paid and CapEx Coverage Ratio | 1.05 | 1.43 | 0.41 | 1.23 | 0.71 |
| Capital Expenditure Coverage Ratio | 2.05 | 2.60 | 0.81 | 3.09 | 1.59 |
| Operating Cash Flow Coverage Ratio | 0.78 | 1.11 | 0.37 | 1.14 | 0.91 |
| Operating Cash Flow to Sales Ratio | 0.19 | 0.22 | 0.07 | 0.24 | 0.18 |
| Free Cash Flow Yield | 2.27% | 2.65% | -0.26% | 2.60% | 0.97% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 98.53 | 51.28 | 73.33 | 56.56 | 79.52 |
| Price-to-Sales (P/S) Ratio | 4.27 | 5.12 | 6.57 | 6.17 | 7.06 |
| Price-to-Book (P/B) Ratio | 1.28 | 1.66 | 2.02 | 1.93 | 1.85 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 44.12 | 37.73 | -390.33 | 38.42 | 103.40 |
| Price-to-Operating Cash Flow Ratio | 22.60 | 23.22 | 90.50 | 26.01 | 38.23 |
| Price-to-Earnings Growth (PEG) Ratio | -1.63 | 2.64 | -3.67 | 1.25 | -5.73 |
| Enterprise Value Multiple | 16.54 | 15.34 | 21.48 | 18.65 | 23.13 |
| Enterprise Value | 11.15B | 13.95B | 17.60B | 16.51B | 15.97B |
| EV to EBITDA | 16.54 | 15.34 | 21.48 | 18.65 | 23.13 |
| EV to Sales | 3.52 | 4.09 | 5.52 | 5.06 | 5.78 |
| EV to Free Cash Flow | 36.45 | 30.18 | -328.37 | 31.52 | 84.71 |
| EV to Operating Cash Flow | 18.67 | 18.57 | 76.14 | 21.33 | 31.32 |
| Tangible Book Value Per Share | 13.05 | 13.29 | 13.06 | 13.20 | 13.28 |
| Shareholders’ Equity Per Share | 13.06 | 13.31 | 13.08 | 13.22 | 13.29 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.07 | 0.18 | 0.18 | 0.19 | 0.19 |
| Revenue Per Share | 3.93 | 4.31 | 4.02 | 4.13 | 3.49 |
| Net Income Per Share | 0.17 | 0.43 | 0.36 | 0.45 | 0.31 |
| Tax Burden | 0.93 | 0.82 | 0.82 | 0.81 | 0.81 |
| Interest Burden | 0.94 | 0.98 | 0.97 | 0.98 | 0.98 |
| Research & Development to Revenue | 0.16 | 0.13 | 0.11 | 0.08 | 0.11 |
| SG&A to Revenue | 0.15 | 0.15 | 0.17 | 0.18 | 0.25 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 4.05 | 1.82 | 0.66 | 1.77 | 1.69 |
Currency in TWD
